No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis

OBJECTIVE: Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Claude, F., Rochat, I., Hafen, G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398262/
https://www.ncbi.nlm.nih.gov/pubmed/30832714
http://dx.doi.org/10.1186/s13104-019-4157-8
_version_ 1783399552202571776
author Claude, F.
Rochat, I.
Hafen, G. M.
author_facet Claude, F.
Rochat, I.
Hafen, G. M.
author_sort Claude, F.
collection PubMed
description OBJECTIVE: Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period. RESULTS: Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.
format Online
Article
Text
id pubmed-6398262
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63982622019-03-13 No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis Claude, F. Rochat, I. Hafen, G. M. BMC Res Notes Research Note OBJECTIVE: Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period. RESULTS: Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature. BioMed Central 2019-03-04 /pmc/articles/PMC6398262/ /pubmed/30832714 http://dx.doi.org/10.1186/s13104-019-4157-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Note
Claude, F.
Rochat, I.
Hafen, G. M.
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_full No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_fullStr No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_full_unstemmed No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_short No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_sort no benefit of longer eradication therapy of pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398262/
https://www.ncbi.nlm.nih.gov/pubmed/30832714
http://dx.doi.org/10.1186/s13104-019-4157-8
work_keys_str_mv AT claudef nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis
AT rochati nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis
AT hafengm nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis

Ejemplares similares